Patient with non‑small cell lung cancer treated with osimertinib – case report

06/2020

MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

We know that non-small cell lung cancer (NSCLC) is a genetically inhomogeneous group of tumors. Demonstration of genetic aberrations then allows us to predict the effectiveness of targeted treatment. Mutations in the epidermal growth factor receptor (EGFR) gene have been investigated for many years. We already have three generations of EGFR tyrosine kinase inhibitors available. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that was first approved for the treatment of patients with locally advanced or metastatic NSCLC with a proven T790M EGFR mutation (FDA 11/2015 and EMA 2/2016). Osimertinib is also currently approved for first-line treatment in patients with a proven activating mutation in the EGFR gene (FDA 4/2018 and EMA 6/18).

Key words

non-small cell lung cancer, epidermal growth factor receptor gene mutation, osimertinib